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ABSTRACT 
Sub-acute/chronic inflammatory diseases are often associated with altered inflammatory 
response, leading to increased host vulnerability to secondary inflammatory challenges. 
In the first study, by employing streptozotocin (STZ)-induced diabetes in mice, we further 
investigate mechanisms leading to enhanced polymorphonuclear leukocytes (PMN) 
response under hyperglycemia. We show that existence of a proinflammatory state 
associated with broad increases of macrophages in various organs plays a dominant role 
in promoting PMN response in diabetic mice. Studies of PMN infiltration during 
zymosan-induced peritonitis reveal that hyperglycemia enhances PMN recruitment 
through increasing F4/80+ macrophages in the peritoneal cavity. Insulin reversal of 
hyperglycemia reduces peritoneal macrophage numbers and ameliorates PMN 
infiltration. Significantly increased macrophages are also observed in the liver, kidneys, 
and intestines under hyperglycemia, and are attributable to exacerbated nephropathy and 
colitis when respective inflammatory conditions are induced. We also find that significant 
monocytosis of inflammatory F4/80+Gr-1+ monocytes from the spleen and macrophage 
proliferation in situ synergistically contribute to the increased macrophage population 
under hyperglycemia. In conclusion, our results demonstrate that STZ-induced 
hyperglycemic/diabetic mice develop a systemic proinflammatory state mediated by 
broad infiltration of macrophages. In the second study, we focus on the identification of 
the carrier that binds to and delivers Shiga toxin 2(Stx2) to the target organ causing 
hemolytic uremic syndrome (HUS). By employing a murine HUS model through co-
injection of LPS-Stx2, we show that, adoptive transfer of CD11b+ leukocytes, but not 
CD11b- leukocytes, RBC, platelets or plasma, isolated from mice with HUS induces HUS 
in healthy recipients. Interestingly, we find that LPS priming of mice significantly 
promotes CD11b+ leukocytes binding to Stx2. Compared to CD11b+ leukocytes from mice 
without LPS priming, CD11b+ leukocytes isolated from mice after LPS priming 
demonstrate higher frequencies of toxin binding and augmented potency to induce HUS. 
In sum, our results demonstrate peripheral CD11b+ myeloid leukocytes act as effective 
Stx2 carriers that deliver toxin to kidneys causing HUS and that LPS-induced 
inflammation enhances the carrier capacity and aggravates HUS. 
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1 INTRODUCTION  
1.1 General introduction 
Chronic diseases are often associated with altered inflammatory response, leading to 
increased host vulnerability to new inflammatory challenges [1-3]. In the first study, by 
employing streptozotocin (STZ)-induced diabetes as a disease model, we further 
investigate mechanisms leading to enhanced neutrophil (polymorphonuclear leukocytes, 
PMN) response under hyperglycemia and compare to that under chronic colitis. We show 
that, different from colitis under which PMN response is significantly potentiated, the 
existence of a proinflammatory state associated with broad increases in macrophages in 
various organs plays a dominant role in promoting PMN inflammatory response in 
diabetic mice. Studies of PMN infiltration during zymosan-induced peritonitis reveal that 
hyperglycemia enhances PMN recruitment not through inducing a high level of IL-17, 
which is the case in colitis, but through increasing F4/80+ macrophages in the peritoneal 
cavity, resulting in elevations of IL-6, IL-1β, TNF-α, and CXCL1 production. Insulin 
reversal of hyperglycemia, but not the neutralization of IL-17, reduces peritoneal 
macrophage numbers and ameliorates PMN infiltration during peritonitis. Significantly 
increased macrophages are also observed in the liver, kidneys, and intestines under 
hyperglycemia, and are attributable to exacerbated nephropathy and colitis when 
inflammatory conditions are induced by doxorubicin and dextran sulfate sodium (DSS), 
respectively. Furthermore, analyses of monocyte production and macrophage 
proliferation in tissues suggest significant monocytosis of inflammatory F4/80+Gr-1+ 
monocytes from the spleen and macrophage proliferation in situ synergistically 
contribute to the increased macrophage population under hyperglycemia. In conclusion, 
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our results demonstrate that STZ-induced hyperglycemic/diabetic mice develop a 
systemic proinflammatory state mediated by broad infiltration of macrophages [4].  
 
In the second study, we focus on another infectious/inflammatory disease, which is 
hemolytic uremic syndrome (HUS) caused by the intestinal infection of Shiga toxin (Stx)–
producing Escherichia coli. HUS is a life-threatening complication characterized by 
hemolytic anemia, acute kidney failure (uremia) and thrombocytopenia, and remains the 
leading cause of acute renal failure in infants and young children [5, 6]. It remains 
uncertain how Stx is transported or delivered from the intestine (original infectious site) 
to the kidney (distant end organ), where it directly damages glomerular epithelial cells [7-
9], since studies have excluded the possibility that Stx spreads by passive dissemination, 
as no free Stx have been detected in the serum of HUS patients. Instead, circulating blood 
cells (e.g., leukocytes) have been suggested to serve as the carrier that delivers Stx to 
distant organs, but the identification of the specific cell type remains controversial [10, 
11]. In this study, by employing a murine HUS model through intraperitoneal co-injection 
of LPS plus Stx2, we further investigate the carrier that delivers Stx2 to the target distant 
organs in vivo. We show that, adoptive transfer of white blood cells (WBC), but not red 
blood cells (RBC), platelets (PLT) or plasma, isolated from mice with HUS is able to 
induce HUS in previously healthy recipients. Ex vivo incubation with Stx2 of isolated 
WBC, RBC or PLT from LPS-primed mice followed by adoptive transfer into recipients 
also confirms that only receiving Stx2 pre-treated WBC, not RBC or PLT, leads to HUS. 
Further separation of WBC into CD11b+ leukocytes (myeloid lineage cells) and CD11b- 
leukocytes (non-myeloid cells) demonstrates that only CD11b+ leukocytes are capable of 
inducing HUS through Stx2 binding and delivering. Interestingly, we found that CD11b+ 
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leukocytes from LPS-primed mice readily induced HUS after exposure to Stx2, whereas 
the same treated CD11b+ leukocytes from healthy mice without LPS priming exhibited 
weaker effects. In conclusion, our results demonstrate that during the development of 
HUS in mice, Stx2 is carried and delivered to the target organs by peripheral CD11b+ 
leukocytes in vivo. Although more investigations are required, these results highly 
suggest that LPS-induced systemic inflammation plays a significant role in “priming” 
CD11b+ leukocytes for binding to Stx2; this effect of LPS renders these leukocytes to 
become effectual toxin carriers resulting in toxin dissemination to distal organs and 
aggravation of HUS. 
 
1.2 Background 
1.2.1 Macrophage-PMN mediated acute inflammation 
Macrophage-PMN mediated inflammation is a central component of many diseases. 
Active inflammation features many pathophysiological conditions including infections by 
various pathogens, and non-infectious tissue/organ disorders such as inflammatory 
bowel disease (IBD), cardiovascular disease, diabetes, arthritis, and even cancer. 
Activation of macrophage-PMN, and their inflammatory responses are the most 
characteristic events during active inflammation and directly impact the consequence of 
the diseases. In general, immune surveillance macrophages first sense the pathogen 
infection or tissue stress, followed by producing a broad spectrum of chemical pro-
inflammatory mediators. These mediators (such as cytokines and chemokines) stimulate 
the nearby microvasculature and induce large amount of polymorphonuclear leukocytes 
(PMN) to rapidly transmigrate across the blood vessel wall, and infiltrate into the 
inflammatory site. After arrival at the site, PMN release potent agents such as reactive 
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oxygen species (ROS), reactive peptides and proteases, as well as perform phagocytosis, 
thereby eliminating pathogens, irritants and damages cells [12-15]. In addition, more 
monocytes are also recruited by the mediators and infiltrate into the inflammatory area. 
These freshly recruited macrophages are pro-inflammatory (classically activated 
macrophages or M1 macrophages), which have enhanced antimicrobial functions 
secreting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and 
interleukin-1beta (IL-1β).  These macrophages also produce nitric oxide (NO) and 
superoxide which brings significant damage to the invading pathogens and irritants. 
Different from cytotoxic CD8+ T cells or natural killer cells, which eliminate aberrant 
particles or cells individually, PMN-mediated destruction is localized and robust. Thus, 
under well-controlled conditions, macrophage-PMN-centered inflammation represents 
the most powerful innate immune mechanism to eliminate pathogens and irritants, as 
well as initiates the process of tissue repairing.  
 
However, vigorous macrophage-PMN functions under dysregulated conditions are the 
underlying causes for exacerbated tissue damage, and often extensively aggravates the 
existing pathological disorders. For instance, in atherosclerosis, macrophage 
accumulation in the atherosclerotic plaques is the major contribution to the non-resolving 
inflammatory response and the progression of this disease [16, 17]. Moreover, during 
acute myocardial attack or cerebral-vascular accident, PMN infiltrating myocardium or 
the brain features prominently at the post-ischemic reperfusion stage and is considered 
to be the major reason leading to further and permanent tissue damage[18-20]. Similarly, 
exaggerated PMN infiltration is the direct cause of tissue/organ damage and loos of 
functions associated with other diseases such as IBD [21-23], and arthritis [24, 25]. 
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Therefore, like a double-edged sword, macrophage-PMN inflammatory response is both 
important and extremely dangerous. Appropriate control of these innate immune cells 
remains as an important mission for improving therapeutics for many diseases. 
 
1.2.2 Diabetes and innate immune cells 
Diabetes mellitus (diabetes) is a disease that has become a massively growing medical 
problem that affects more than 300 million people throughout the world (7% of the 
world’s adult population). Patients with diabetes have an increased susceptibility to 
develop many complications such as infection, skin lesion, cardiovascular disease, and 
diabetic nephropathy leading to end stage renal failure [26-30]. Persistent or poorly 
controlled hyperglycemia contributes to an elevation in both morbidity and mortality in 
diabetic patients. It is a worldwide disease spreading not only in developed countries, but 
also in developing ones. In USA, the total estimated cost of diagnosed diabetes in 2012 is 
$245 billion, including $176 billion in direct medical costs and $69 billion in reduced 
productivity. Therefore, diabetes and its complications are critical medical concerns that 
are threatening the economy and public health of the entire world.  
 
Diabetes is a disorder of the metabolism identified by hyperglycemia (high blood glucose 
level) resulting from insufficient insulin producing (type 1 diabetes), or insulin resistance 
(type 2 diabetes). Both type 1 and type 2 diabetes have been characterized not only as 
metabolic but also immune disorders. Macrophage-PMN-mediated inflammatory 
response is a central component that contributes to the progression of diabetes and its 
complications, such as skin lesion, atherosclerosis and chronic kidney disease [28-30], 
and is believed to provide a significant connection that links immune dysfunction and 
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metabolic disorder [31]. The studies of mechanisms that regulate innate immune cells in 
diabetes are intricate, and even controversial in many aspects. Previous studies showed 
that adhesion, chemotaxis and phagocytosis of macrophage and PMN in diabetes were 
both impaired [32, 33], while other studies show adhesion, migration and TNF-α 
production of macrophages are enhanced by hyperglycemia [34]. In contract to healthy 
controls stimulated with LPS, monocytes from patients with type 1 diabetes produced 
higher amount of pro-inflammatory cytokine IL-6 [32]. Hyperglycemia also elevated 
monocyte-chemoattractant-protein-1 (MCP-1) production from diabetic endothelial cells, 
thus attracting more macrophages that potentially promoted arteriosclerosis [35]. 
Moreover, obesity in type 2 diabetes triggered monocytes infiltrating into the adipose 
tissue, where these infiltrated monocytes/macrophages further promoted insulin 
resistance via producing pro-inflammatory cytokines [36, 37]. Collectively, the effects of 
hyperglycemia on macrophage-PMN function and response are still largely unknown and 
required further addressed. 
 
As the word origin of Diabetes Mellitus meaning “to pass through (excessive discharge of 
urine) honeyed or sweet”, hyperglycemia is the very character shared by all types of 
diabetes that results in a global micro-environmental change to the whole-body systems 
including immune system. Persistent or poorly controlled hyperglycemia contributes to 
an elevation in both morbidity and mortality in diabetic patients. Therefore, 
understanding the direct regulation of hyperglycemia to macrophages-PMN response is 
extremely urgent and clinically significant.  
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1.2.3 Shiga toxin and hemolytic uremic syndrome 
1.2.3.1 Disease background 
Shiga toxin (Stx)-producing E. coli (STEC) represents a serious life-threatening food 
borne pathogen and is a major health problem still in the United States and world-wide. 
It is estimated that STEC causes over 265,000 illnesses each year in the US with more 
than 3,600 hospitalizations and 30 deaths [5]. Infections caused by STEC lead to 
bacterial-induced intestinal inflammation characterized by heavy diarrhea (watery and 
bloody) and colitis. However, the subsequent development of hemolytic uremic syndrome 
(HUS), which is characterized by microangiopathic hemolytic anemia, thrombocytopenia, 
and acute renal failure, is the main reason for the high rates of mortality associated with 
such disease [7, 38, 39]. In fact, HUS is the leading cause of renal failure in infants and 
young children [40, 41]. The inability to predict which patients will recover spontaneously 
and which will develop HUS remains a significant dilemma for clinicians [42]. HUS 
develops at the post-acute stage of infection and is associated with the spread of Shiga 
toxin (Stx) from the intestines to other distal organs, such as the kidney. Currently there 
are no specific therapeutics available for treatment of STEC-associated HUS, and therapy 
is primarily supportive. A major obstacle in combating HUS is that traditional antibiotic 
therapy is contraindicative because it shows promotion of toxin expression from the 
lysogenized phage that typically carries Shiga toxin (Stx) genes, thus, exacerbating the 
infection [43]. Therefore, novel therapeutic strategies are urgently needed for controlling 
this serious infectious disease. 
 
E. coli O157:H7, the strain most frequently associated with the development of HUS, was 
first described in 1982 in four patients with bloody diarrhea [44]. The initial outbreak was 
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associated with two outlets of the same fast-food chain, and illness was linked to 
undercooked hamburgers. Many outbreaks have occurred since then with one of the most 
severe occurring from May 2011- July 2011 in several European countries, particularly 
northern Germany (Hamburg), which experienced one of the largest death tolls related to 
HUS ever reported [45]. More recently, other sources for E. coli 0157:H7 have been 
identified, including apple juice and cider; raw vegetables such as lettuce and spinach; 
raw milk; and processed foods such as salami [46].  
 
1.2.3.2 Shiga toxin 
STEC produces two types of bipartite toxins, Stx1 and Stx2, which belong to a large family 
of prokaryotic A:B toxins that include, pertussis, diphtheria, cholera, and ricin [47] and 
consists of one large enzymatically active A subunit (~32 kDa) and 5 smaller B subunits 
(~8 kDa each). The holotoxin binds via the B- subunit pentamer to the lipid raft-
associated glycolipid receptor globotriacylceramide (Gb3), located on the surface of target 
cells, in particular the kidney glomerular endothelium, where the expression of the Stx 
receptor is most abundant [48]. After toxin uptake by way of endocytosis, Stx undergoes 
retrograde trafficking through the Golgi apparatus and endoplasmic reticulum to the 
cytosol, where it specifically cleaves an adenine from the 28S rRNA, inactivating the 
ribosome and inhibiting protein synthesis [49]. Additionally, it has been found that Stx 
also depurinates DNA, resulting in host cell apoptosis [8].  
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1.2.3.3 Potential carriers of Stx 
For non-invasive STEC to cause HUS, Stx must be delivered or transported from the 
intestine to the kidney. It remains a dilemma how Stx travels from STEC-infected 
intestines to kidneys, though studies have excluded the possibility that Stx spreads by 
passive dissemination, as no free Stx have been detected in the serum of HUS patients. 
Instead, circulating leukocytes have been suggested to serve as the carrier that delivers 
Stx to distant organs [10, 11]. In human, PMN have been implicated to be the carrier. 
Direct binding of Stx to human PMN was observed and this binding was interfered by 
LPS, suggesting Toll-like receptor 4 (TLR4) to be the receptor [10, 50-52]. However, other 
studies either failed to replicate Stx-neutrophil binding or demonstrated that the binding 
was rather weak and unspecific, raising uncertainty of whether PMN are the toxin carrier 
[53, 54]. Stx binding to leukocytes was also shown using isolated porcine peripheral blood 
leukocytes in vitro; however, whether these leukocytes were responsible for toxin delivery 
in vivo leading to HUS was not studied [55]. In mice, a study demonstrated that Stx2 was 
capable of binding to neutrophils, but this binding is through Gb3 and leads to the toxin 
internalization. Therefore, this study not only contradicted to the finding in humans in 
which Stx-neutrophils binding is independent of Gb3 [56], but also raised a question of 
whether neutrophils would deliver toxin without degrading it intracellularly. In addition 
to these dilemmas, a recent study found Stx in serum microvesicles, further baffling the 
exact carrier for Stx elusive. Moreover, most of the above experiments identifying the 
toxin carrier were in vitro cell binding assays, and there is a need for approaches that 
determine the relevance of Stx delivery causing the actual disease of HUS in vivo. 
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1.3 Murine disease models 
1.3.1 STZ-induced hyperglycemia/type 1 diabetes 
STZ, originally identified as an antibiotic in the late 1950s [57], has been widely used to 
induce diabetes/hyperglycemia in experimental animals [58]. STZ is a glucose analog 
(glucosamine-nitrosourea compound), which enters the pancreatic β cells through 
glucose transporter 2 that is highly expressed on the surface of β cells [59, 60]. STZ is 
highly toxic to β cells by causing DNA alkylation, which induces the activation of poly 
ADP-ribosylation, a process that contributes to the diabetogenicity of STZ more than DNA 
damage itself [61]. As shown in Figure 1, poly ADP-ribosylation results in the depletion of 
NAD+ and ATP, and the augmented ATP dephosphorylation increases the supply of 
substrate for xanthine oxidase, which elevates the production of superoxide radicals. 
Moreover, STZ also increases the amount of nitric oxide to a toxic level. Consequently, 
pancreatic β cells undergo necrosis due to the action of STZ, and production of insulin is 
ceased, therefore resulting in permanent hyperglycemia/type 1 diabetes, which can be 
temporarily reversed after the administration of insulin. 
 
To induce permanent hyperglycemia/diabetes, STZ is administrated intravenously, 
intraperitoneally, or subcutaneously into the experimental animal, usually in multiple low 
doses (30-50 mg/kg). During the first several days, animal may develop hypoglycemia 
due to a transient insulitis that is also caused by STZ [58]. After 10-14 days, hyperglycemia 
will be developed, and remain for the rest of life. There are several advantages of utilizing 
this STZ-induced diabetic mouse model compared to other models (e.g., high-fat-diet-
induced type 2 diabetes). First, hyperglycemia is the only major inflammatory 
pathogenesis in this STZ model, where no other systemic inflammatory factors, such as 
11 
obesity, are involved, therefore providing a more isolated/independent system for the 
purpose of studying the regulation of immune system under hyperglycemic condition. 
Second, STZ induces type 1 diabetes, which is insulin dependent that can be 
treated/reversed by the administration of insulin, thus affording a high degree of 
controllability and reproducibility.  
 
 
Figure 1.1 The mechanism of STZ-induced toxic events in β cells of rat pancreas.  
MIT-mitochondria; XOD-xanthine oxidase[61] 
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1.3.2 DSS-induced colitis 
Heparin-like polysaccharide DSS is the most common chemical used to induce 
experimental colitis in mice [62, 63]. By routinely administration of DSS within daily 
drinking water, a form of mouse colitis is developed that mimics the clinical and 
histological features of human ulcerative colitis (a form of IBD in human), as a dose 
dependent manner [64]. Characteristics of DSS-induced colitis include weight loss, 
diarrhea, bloody stool, reduced colon length, loss of colon epithelial tissue, and crypt 
architecture disruption. Proinflammatory cytokines and chemokines, such as IL-1β, IL-6, 
IL-8, and TNF-α, are markedly elevated, which results in the recruitment of circulating 
inflammatory monocytes/macrophages, and most predominantly PMN into the distal 
colon. Furthermore, marked elevation of IL-17 at the post-acute/chronic stage [1, 21, 65, 
66] of DSS-induced colitis has been observed. According to our studies and studies by 
others [67-70], under the colitic condition, IL-17 is tightly associated with enhanced PMN 
response through at least two mechanisms: i) promoting granulopoiesis, thus increasing 
the PMN supply, and ii) potentiating PMN response leading to enhanced PMN 
chemotaxis, ROS production, etc.   
 
After the administration of DSS, the epithelial monolayer lining the distal colon is 
damaged, which allows the dissemination of proinflammatory intestinal contents (e.g., 
bacteria and their products) into the lamina propria.  However, the mechanism of how 
DSS causes disruption in the distal colon remains unknown. Some studies suggest that 
dextran sulfate inhibits ribonuclease action [71, 72], but the mechanism of how DSS 
penetrates the cell is also unclear. Recent studies indicate that DSS combines with 
medium-chain-length fatty acids that are present in the colonic lumen to form nano-
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lipocomplexes, which are able to fuse with colonocyte membranes and further activate 
downstream inflammatory signaling pathways inside the cytoplasm [73]. Nevertheless, 
DSS-induced colitis is a well-recognized, simple, and consistent model for assessing both 
acute and chronic colitis.  
 
1.3.3 LPS-Stx2-induced hemolytic uremic syndrome 
This murine HUS model was first established by Keepers et al. [74] by the intraperitoneal 
administration of Stx2 combined with LPS. Neither Stx2 nor LPS alone is able to mimic 
HUS in the mouse, but combining Stx2 with LPS recapitulates the human HUS in both 
clinical signs and symptoms, including the clinical diagnostic hallmark triad of hemolytic 
anemia, thrombocytopenia, and renal failure [5]. In particular, increased reticulocytes 
and Howell-Jolly bodies that are observed in this murine model demonstrate hemolytic 
anemia. A very low platelet count represents thrombocytopenia. Elevated serum 
creatinine and blood urea nitrogen (BUN) levels are the evidence of renal 
dysfunction/renal failure. The mice also exhibit neutrophilia and monocytosis that are 
described in clinic studies [38, 41]. Pathological changes in the glomeruli of kidney tissue 
are consistent with the features of clinical HUS.   
 
In our study for the identification of the potential carrier of Stx2 in mice with HUS, to 
establish a steady HUS model, we utilized the LPS plus Stx2 administration strategy. In 
particular, mice were first intraperitoneally injected with LPS, 24 hours prior to the Stx2 
intraperitoneal administrations for three times in a 24-hour-interval. As early as 24 hours 
after the first dose of Stx2 injection, the complete HUS triad of hemolytic anemia, 
thrombocytopenia, and renal dysfunction begun to develop in the mice.  In summary, co-
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injection of LPS and Stx2 intraperitoneally is sufficient to recapitulate human HUS in 
experimental mice, which provides a reproducible model for the study of HUS. 
Furthermore, it does not require live bacteria, since HUS is a toxemia but not a bacteremia 
[42].  
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2.1 Introduction 
An active inflammatory response often starts in local tissues where afflicted cells and 
immunological surveillance cells (viz. tissue macrophages) respond to infection and/or 
injury, and produce potent proinflammatory mediators [12-15]. These mediators (i.e. 
cytokines, chemokines, lipids, and complements) stimulate the nearby microvasculature 
and attract peripheral PMN to transmigrate across endothelial linings and infiltrate 
inflammatory tissues. These inflammatory PMN then perform potent anti-pathogen and 
tissue-damaging functions to eliminate infectious aliens and remove injured cells [75-78]. 
Effectively mounting such a leukocyte-centered inflammatory response is imperative for 
innate immunity; failure of this response directly indicates immune deficiency [79-84]. 
However, exaggerated leukocyte inflammatory response is detrimental, often leading to 
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aggravated tissue damage and prolonged disease conditions [17, 23-25, 85, 86]. 
Therefore, like that of a double-edged sword, active inflammation is extremely important, 
but also highly dangerous.  
 
The specific mechanisms that control this inflammatory response under various disease 
conditions vary and remain an enigma. In our previous studies of zymosan-induced 
peritonitis in mice, we had observed that PMN infiltration into the peritoneum is 
significantly enhanced in mice that had been preconditioned with colitis, type-1 diabetes, 
or other chronic inflammatory conditions [1, 2]. Furthermore, the enhanced PMN 
response under colitis was found to be associated with marked elevation of IL-17 at the 
post-acute/chronic stage [1, 21, 65]. According to our studies and also studies by others 
[67-70], IL-17 promotes PMN inflammatory response through at least two mechanisms: 
i) promoting granulopoiesis, thus increasing the PMN supply, and ii) potentiating PMN 
response leading to enhanced PMN chemotaxis, ROS production, etc.  However, it is 
unclear whether IL-17 plays an essential role as well in enhancing PMN response under 
other conditions.  
 
In this study, we further examined mechanisms that enhance PMN response under 
diabetes using an STZ-induced type-1 diabetes model. We found that IL-17 plays a 
negligible role in this condition; instead, diabetes-associated hyperglycemia induces a 
significant expansion of the macrophage population in multiple organ tissues. This 
increased population disposes a systemic hypersensitive state that, upon inflammatory 
challenge, triggers a hyper-inflammatory reaction and increases proinflammatory 
cytokines and chemokines through which promote PMN infiltration. 
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2.2 Materials & Methods 
2.2.1 Mice & Disease models 
C57BL/6 mice (6-10 weeks old, 18-22g) and B6.Cg-Lepob mice (ob/ob mice, 10-12 weeks 
old, 35-40g) were purchased from The Jackson Laboratory and were housed in a 
pathogen-free animal facility. STZ-induced type 1 diabetes [87-89] was established by 
subcutaneous (s.c.) administration with STZ (Sigma-Aldrich, freshly prepared in citrate 
buffer, pH 4.5), at the dose of 50 mg/kg of body weight or a lower dose, 25 mg/kg of body 
weight (volume: 0.2 ml per mouse), for five consecutive days. Diabetes/hyperglycemia 
was confirmed by testing the blood glucose level using the OneTouch® glucose monitoring 
system (LifeScan). To treat diabetic mice with insulin, STZ-injected mice with confirmed 
hyperglycemia (blood glucose level > 200mg/dl) were administered with insulin (1UI/kg, 
0.2 ml, s.c.) twice a day.  
 
To induce colitis, 2% DSS (MP Biomedicals) dissolved in pure water was given to mice as 
the drinking water [1]. The colitis disease activity index (DAI) was determined by 
combining scores of 1) body weight loss (0, none; 1, 1-5%; 2, 5-10%; 3, 10-15%; 4, >15%), 
2) stool consistency (0, normal; 2, loose stool; 4, diarrhea), and 3) stool blood (0, negative; 
2, positive; 4, gross bleeding) [90].  
 
To induce peritonitis, 0.5 mg zymosan (zymosan A, Sigma-Aldrich) in 0.5 ml PBS was 
given intraperitoneally (i. p.) [91]. At different time points (0, 2, 4, 6, 8 and 16 h) following 
the zymosan administration, mice were euthanized and cells inside the peritoneum were 
lavaged into 5ml PBS. Total peritoneal cell numbers were counted under the microscope. 
PMN that infiltrated the peritoneum were labeled with fluorophore-conjugated anti-
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mouse Ly6G antibodies (BioLegend, 1:1000, room temperature, 2 h), and analyzed by 
flow cytometry.  
 
Doxorubicin-induced nephropathy was established by intravenous (i.v.) administration 
of doxorubicin hydrochloride (Sigma-Aldrich) at doses of 20 mg/kg or 30 mg/kg (in 0.3 
ml PBS, i.v. once) [92, 93]. Urine samples were collected daily via gentle bladder massage 
and proteinuria was tested using an Albumin Mouse ELISA kit (Abcam) according to the 
manufacturer’s protocol. At day 7 of doxorubicin (30 mg/kg, once) administration, mice 
were euthanized, kidneys were harvested and excised for immunohistochemistry (IHC) 
staining described blow. 
 
2.2.2 Tissue sectioning and staining 
Kidney, liver, and colon tissues excised from mice were embedded in Richard-Allan 
Scientific™ Neg-50™ frozen section medium (Thermo Scientific) followed by sectioning 
at a thickness of 10µm using a Cryostat microtome. For immunohistochemistry (IHC) 
staining, the tissue slides were treated with 0.1% H2O2, followed by blocking with 10% 
normal goat serum (NGS). Macrophage staining was performed using a rat anti-mouse 
F4/80 antibody (BioLegend, 1:500) at 4oC for 16 h, and an HRP-conjugated goat anti-rat 
secondary antibody (1:2000, room temperature, 30 mins), followed by color development 
using 3, 3'-diaminobenzidine (DAB) (BD Biosciences). Tissue counterstaining was 
performed using hematoxylin (8 mins). For immunofluorescence (IF) staining, NGS-
blocked tissue sections were incubated with Alexa Fluor 488-conjugated anti-mouse 
F4/80 antibody (BioLegend, 1:500, room temperature, 2 h) or a non-conjugated anti-
F4/80 antibody (1:500, room temperature, 2 h) followed by detection using Alexa Fluor 
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594-conjugated goat anti-rat IgG (Invitrogen, 1: 2000, room temperature, 30 mins). To 
test macrophage proliferation in situ, tissue sections were permeabilized with 0.05% 
Triton X-100 in PBS, and stained with a FITC-conjugated anti-mouse Ki-67 antibody 
(BioLegend, 1:500, room temperature, 2 h).  
 
2.2.3 Leukocyte adoptive transfer 
Total bone marrow cells were obtained by flushing femur cavities of healthy mice and 
diabetic mice. After lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 
0.1 mM EDTA), cells were applied to Percoll™ (GE Healthcare) density gradients to 
separate mature PMN (1800xg, 18°C, 40 mins), which were settled at the interface 
between Percoll densities of 60% and 70% [94].  The obtained PMN samples of healthy 
mice and diabetic mice were then separately labeled with orange and green fluorescence 
dyes, 5,6-((4-chloromethyl) benzoyl) amino) tetramethylrhodamine (CMTMR, Life 
Technologies) and carboxyfluorescein succinimidyl ester (CFSE, Life Technologies), 
respectively. For adoptive transfer, CMTMR and CFSE-labeled PMN (1.5 x 106 cells each 
color) were mixed and intravenously (i.v.) injected into a recipient mouse through a tail 
vein. To test PMN response in vivo, zymosan-peritonitis was induced in recipient mice as 
described earlier and fluorescence-labeled PMN infiltration into the peritoneal cavity at 
2 h post-zymosan injection was analyzed microscopically after the peritoneal lavage.   
 
2.2.4 Reactive oxygen species (ROS) assay 
A luminal-based assay was used to test PMN production of ROS upon phorbol myristate 
acetate (PMA) (Sigma-Aldrich) stimulation. Briefly, isolated PMN (1 x 106) from bone 
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marrow as described earlier were incubated in HBSS (with calcium and magnesium) 
containing 1mM luminol (Sigma-Aldrich) at 37°C. After stabilization, PMN were 
stimulated with PMA (1µM) and photons released from the reaction were immediately 
recorded at a 30-second interval for 30 minutes using a microplate luminometer (LMax 
II 384, Molecular Devices), followed by analyses using a SoftMax Pro software (Molecular 
Devices). 
 
2.2.5 Measurement of cytokines 
Whole blood from mice was collected without anti-coagulation and the serum was 
isolated through centrifugation (2000xg, 4°C, 5 mins). Cytokines including IL-1β, IL-4, 
IL-6, IL-10, IL-17A, IFN-γ, TNF-α, MCP-1, G-CSF and GM-CSF in the serum were assayed 
by standard sandwich ELISA in 96-well plates using capture and detecting antibodies 
obtained from BD Biosciences or BioLegend. Purified recombinant murine cytokines 
purchased from PeproTech were used as positive controls and concentration references. 
To detect cytokines released by in vitro-treated macrophages, F4/80+ peritoneal 
macrophages obtained from mouse peritoneal lavage were cultured in the 24 well-culture 
dish for 16 h and treated with zymosan (0.1 mg/ml, 37oC). At different time points after 
the administration of zymosan, the cell-free supernatants were collected, followed by 
ELISA detection of cytokines.   
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2.2.6 Flow cytometry assays of leukocytes from peripheral blood, spleen 
and bone marrow 
Mouse peripheral blood were collected by cardiac puncture with anti-coagulation (0.1 
mM EDTA). After lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 
0.1 mM EDTA), white blood cells were collected followed by labeling with fluorophore-
conjugated antibodies against murine Gr-1 and F4/80 (both from BioLegend, 1:1000, 
room temperature, 30 mins) and analyses by flow cytometry (LSR Fortessa, BD 
Biosciences). Mouse splenocytes were isolated from the whole spleen, and bone marrow 
leukocytes were harvested from mouse femur and tibia bones. After lysis of RBC, these 
cells were labeled with fluorophore-conjugated anti-mouse Ly6C and Ly6G antibodies 
(both from BioLegend, 1:1000, room temperature, 30 mins) followed by flow cytometry 
analyses. In particular, monocytes populations were represented by F4/80+ cell groups in 
the peripheral blood, or Ly6Chigh cell groups in the spleen and the bone marrow. PMN 
populations were represented by Gr-1++ F4/80- cell groups in the peripheral blood, or 
Ly6Ghigh cell groups in the spleen and the bone marrow.  
 
2.2.7 Statistical analyses 
Data represent at least three independent experiments and are expressed as the mean ± 
SD. Normal distributed variables were compared using Student’s t-test. The reported p 
value was 2-tailed. Differences were considered statistically significant at P < 0.05, as 
analyzed using the Student t-test for paired samples and one-way ANOVA for k > 2 
samples. 
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2.3 Results 
2.3.1 Distinctive mechanisms regulate PMN response under STZ-induced 
diabetes and DSS-induced colitis 
Previously, we had observed that mice under different inflammatory conditions, 
including STZ-induced diabetes and DSS-induced colitis, experience enhanced PMN 
inflammatory response [1]. In particular, we found that this PMN phenotypic change 
under colitis is associated with IL-17 induction. In this study, we further investigated 
mechanisms that cause the PMN response change under STZ-induced diabetes. As shown 
in Figure 2.1 A, mice administered with STZ rapidly developed hyperglycemia in a few 
days, where a higher dose (50 mg/kg, 5 x) led to a blood glucose level of 350-550 mg/dl 
and a lower dose (25 mg/kg, 5 x) led to a blood glucose level varying between 200-400 
mg/dl. Furthermore, the hyperglycemic condition was maintained for an extended period 
of time unless given insulin, which mitigated hyperglycemia in STZ-treated mice. We 
further separated mice into two groups: one group had the blood glucose between 200-
350 mg/dl, and the other group had a relatively higher level, >350 mg/dl.  To study how 
hyperglycemia affects PMN response, two groups of diabetic mice with different levels of 
blood glucose, or with insulin treatment, were i.p. challenged with zymosan to induce 
acute peritonitis. As shown in Figure 2.1 B, zymosan challenge induced rapid PMN 
infiltration into the peritoneum for all mice. However, when comparing mice without STZ 
administration (ctl.) and those with STZ-induced hyperglycemia, the latter displayed a 
significant increase in the number of PMN as well as an earlier onset during which PMN 
infiltrate. Specifically, more than 5 x 106 PMN were accumulated in the peritoneum of 
mice with hyperglycemia at 2 h post the zymosan challenge, whereas only minimal PMN 
infiltration was detected in non-diabetic control mice. When PMN infiltration had 
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climaxed (4-6h), hyperglycemic mice had displayed a greater number of PMN infiltrating 
the peritoneum than that of the control. There were only slight differences in PMN 
response in hyperglycemic mice with blood glucose level of 200-350 mg/dl versus those 
of > 350 mg/dl. Through insulin treatment, the alleviation of the hyperglycemic condition 
completely eliminated the enhanced PMN inflammatory response, both the onset and the 
increased number, during zymosan-induced peritonitis.   
 
Indeed, the manner of enhanced PMN infiltration at 2 h post-zymosan challenge in mice 
with hyperglycemia was highly similar to that in mice with chronic colitis (Figure 2.1 C). 
Colitis in mice was induced by 2% DSS via drinking water (Figure 2.1 D), and, consistent 
with our previous studies, IL-17 was significantly induced when colitis lasted over 8-9 
days [1, 2]. Experimental colitis is associated with prominent induction of IL-17 had also 
been reported by others [66]. Testing zymosan-induced peritonitis in mice with a high 
level of IL-17 on day 10 of DSS-induced colitis observed markedly enhanced PMN 
infiltration into the peritoneum (Figure 2.1 C). Consistent with previous reports [1, 2, 66], 
this colitis-associated enhancement of PMN response was associated with the effect of IL-
17, as it could be eliminated by IL-17 neutralization (Figure 2.1 C). In contrast, 
neutralization of IL-17 in mice with hyperglycemia, either 200-350 mg/dl or >350 mg/dl, 
failed to reduce PMN infiltration (Figure 2.1 C). Analyses of cytokines in serum confirmed 
different cytokine profiles in mice with colitis versus those with hyperglycemia. In 
particular, IL-17 was highly elevated only in mice under colitis, but not hyperglycemia 
(Figure 2.1 E). In fact, no particularly high levels of cytokines, except moderate increases 
in IL-6 and MCP-1 (Figure 2.1 E), were detected in mice with hyperglycemia for even 5 
months. Thus, although colitis and hyperglycemia both displayed enhancement of PMN 
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inflammatory response, the key mechanism involved in these two conditions are 
different. IL-17, which is essential in colitis, plays a trivial role in regulating PMN response 
under hyperglycemia. 
 
Since a previous study has shown that PMN function was primed under colitis [1], we 
tested if this would also be the case in mice with hyperglycemia. For these experiments, 
PMN samples isolated from different mice were tested for ROS production upon PMA 
stimulation.  As shown in Figure 2.1 F, compared to PMN from control mice, PMN from 
mice with colitis and hyperglycemia both displayed increased ROS production; however, 
the former PMN consistently displayed even higher levels than the latter. These results 
suggest that PMN under hyperglycemia and colitis were both functionally primed; 
however, the condition of colitis provided a mechanism that is more potent in priming 
PMN than that of hyperglycemia. Again, IL-17 played an essential role in colitis but not 
hyperglycemia; neutralization of IL-17 reversed the enhanced ROS production in PMN 
isolated from colitic, but not diabetic, mice (Figure 2.1 G).   
 
2.3.2 Hyperglycemia increases peritoneal macrophage population and 
escalates zymosan-induced peritonitis 
Despite that PMN displayed less priming under hyperglycemia compared to colitis, the 
enhanced PMN recruitment during peritonitis in mice under either condition was similar 
(see Figure 2.1 B). These results suggest that another mechanism(s), in addition to PMN 
priming, synergistically promotes PMN response under hyperglycemia. To identify this 
mechanism(s), we further analyzed zymosan-induced peritonitis and found that 
inflammatory cytokines produced in mice with hyperglycemia were much higher than 
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mice with colitis. As shown in Figure 2.2 A, significantly higher levels of IL-6 and CXCL1 
(also termed KC or IL-8) were detected in the peritoneal cavity and in the serum during 
peritonitis in hyperglycemic mice than those in colitic mice, and both being higher than 
those in the control. This suggests that macrophage inflammatory responses in peritonea 
of hyperglycemic and colitic mice were upregulated. We lavaged peritoneal F4/80+ 
macrophages, the principle cells producing IL-6 and CXCL1 [95, 96], and examined their 
function ex vivo. Interestingly, lavaging the peritoneum of hyperglycemic mice recovered 
more than double the amount of F4/80+ macrophages than those recovered in colitic and 
control mice. As shown in Figure 2.2 B, more than 17 x 105 macrophages were recovered 
from hyperglycemic mice with blood glucose levels below or above 350 mg/dl, versus 8.4 
± 1.5 x 105 and 8.1 ± 0.5 x 105 from colitic and control mice, respectively. Furthermore, 
treatment of diabetes with insulin reduced the number of macrophages in the 
peritoneum. Testing cytokine production from peritoneal macrophages by zymosan 
challenge ex vivo revealed markedly higher levels of total IL-6, CXCL1, IL-1β, and TNF-α 
produced by macrophages from hyperglycemic peritoneum than those from colitic, 
control, or insulin-treated mice (Figure 2.2 C, Total). However, these increases were 
contingent upon higher macrophage numbers; calculation of cytokine production by 
isolated macrophages revealed that individual macrophages from hyperglycemic mice did 
not produce more cytokines than control macrophages from healthy mice, and actually 
lower levels than macrophages from colitic mice (Figure 2.2 C, Individual). Therefore, 
these results suggest that increases in the macrophage number, but not the macrophage 
functionality, served as a dominant reason for promoting the macrophage-mediated 
inflammatory response during zymosan-induced peritonitis in hyperglycemic mice. In 
contrast, macrophages from colitic mice displayed increases in cytokine production 
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individually, suggesting these macrophages were functionally primed. In addition, we 
observed that macrophages from insulin-treated mice produced much less TNF-α than 
those from healthy mice (Figure 2.2 C), and this has also been reported previously [97, 
98]. 
Thus, the increased macrophages in the peritoneum under hyperglycemia likely played a 
critical role, in addition to moderate PMN priming, in promoting an inflammatory 
response during peritonitis. To further test the role of peritoneal microenvironment, we 
performed PMN adoptive transfer experiments. For these experiments, PMN isolated 
from healthy and hyperglycemic mice were labeled with CMTMR (red) and CFSE (green), 
respectively, and then were mixed at 1:1 ratio followed by transfer into healthy or diabetic 
mice. Zymosan-induced peritonitis was subsequently induced in the recipient mice. In 
healthy recipient mice, CFSE-labeled PMN that originated from hyperglycemic mice 
displayed slightly more (~20%) infiltration than CMTMR-labeled PMN that were from 
healthy mice (Figure 2.2 D-E). This confirmed that PMN from the donor hyperglycemic 
mice were moderately primed.  However, in recipient mice that were hyperglycemic, not 
only CFSE-labeled PMN from diabetic mice, but also CMTMR-labeled PMN from healthy 
mice, displayed enhanced infiltration, though the former was greater. At 2 h post-
zymosan administration, double the number of PMN (green or red) infiltrated the 
peritoneum in hyperglycemic recipients than that in healthy recipients. As expected, 
insulin treatment of recipient mice completely eliminated the promoting effect on PMN 
infiltration by diabetes. Together, these results confirmed that the hyperglycemic 
peritoneum, which had increased numbers of macrophages and produced elevated 
proinflammatory cytokines, significantly promoted PMN infiltration during peritonitis 
challenge.  
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2.3.3 Hyperglycemia induces broad macrophage infiltration in organ 
tissues  
The condition of hyperglycemia also induced increases in macrophage population in 
multiple other organs. As shown in Figure 2.3 A, IHC and IF staining of liver sections 
revealed marked increases in F4/80+ macrophages lining along endothelial surfaces of 
portal vein branches and within sinusoids between hepatocytes in hyperglycemic mice. 
Furthermore, this pathological change was further exacerbated when diabetes prolonged 
without insulin alleviation. As shown, liver tissues harvested from mice with 
hyperglycemia for five months displayed more extensive macrophage infiltration than 
those from mice with hyperglycemia for one month. Two groups of mice with blood 
glucose levels below and higher than 350 mg/dl showed similar results. In addition, the 
liver structure appeared to be deteriorated after prolonged hyperglycemia. Compared to 
liver tissues harvested from healthy control mice and the one-month hyperglycemic mice, 
the tissue from mice with five-month hyperglycemia exhibited a structurally “loose” 
appearance; having displayed deteriorated or shrank hepatocyte lobules, and enlarged 
sinusoids that were accumulated with many F4/80+ macrophages (Figure 2.3 A).  
 
Increases in macrophage infiltration were also found in kidneys under hyperglycemia. As 
shown in Figure 2.3 B, kidney tissues around the glomeruli, where macrophages are 
usually absent, displayed strong staining for F4/80+ macrophages in mice with 
hyperglycemia. Increases in F4/80+ macrophages were also observed along the afferent 
and efferent vessels and renal tubules. Again, this condition of macrophage infiltration in 
kidney was exacerbated when hyperglycemia prolonged from one month to five months. 
Further examination for macrophage phenotypes with the M1 and M2 markers, CD86 and 
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Dectin-1, respectively, failed to observe definitive staining (Figure 2.3 E). These results 
suggest that the increased macrophages in tissues were phenotypically undetermined.  
 
Next, we asked the question of how hyperglycemia caused an increase of macrophage 
population in tissues. One possibility is that hyperglycemia induces monocytosis and that 
elevated monocyte infiltration into tissues results in an increase of macrophage numbers. 
Another possibility is that hyperglycemia stimulates macrophage proliferation in situ. To 
address the first possibility, we examined monocytes in the peripheral blood and found 
that the population of Gr-1+F4/80+ monocytes, the major tissue-infiltrating monocytes 
[99, 100], was significantly expanded in hyperglycemic mice. As shown in Figure 2.4 A, 
peripheral Gr-1+F4/80+ monocytes were elevated more than two-fold in hyperglycemic 
mice compared to that of the control. In contrast, peripheral Gr-1-F4/80+ monocytes, also 
termed resident monocytes, changed only slightly. Insulin treatment of diabetes reversed 
the elevation of peripheral Gr-1+F4/80+ monocytes. Since monocytes can be produced by 
the spleen and bone marrow [101-103], we further examined monocytes in these organs. 
As shown in Figure 2.4 A, the spleen, but not bone marrow, displayed expansion of 
monocytes (Ly6Chigh) under hyperglycemia, suggesting that expansion of monocytes in 
the circulation were most likely due to increased spleen production. We also tested if 
macrophage proliferation in situ served as another mechanism for increasing tissue 
macrophages under hyperglycemia. Studies have reported that some tissue macrophages 
are formed during embryonic development and are capable of self-replenishing through 
proliferation in situ [104-106]. As shown in Figure 2.4 C and D, the majority (> 80%) of 
macrophages in the liver and kidneys of hyperglycemic mice displayed positive staining 
for the cell proliferation marker Ki-67, suggesting that these macrophages were 
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undergoing active proliferation. Comparably, the few macrophages observed in the same 
tissues of healthy mice were largely devoid of Ki-67 staining. Examination of F4/80+ 
peritoneal macrophages from hyperglycemic mice also observed a high rate of 
proliferation (> 90% positive of Ki-67 staining). Therefore, broadly increased 
macrophages in tissues under hyperglycemia are likely the collective results of augmented 
monocyte infiltration and macrophage proliferation in situ. Moreover, we also observed 
an expansion of PMN population in the peripheral blood (Gr-1+F4/80-) and bone marrow 
(Ly6Ghigh) under hyperglycemia (Figure 2.4 A-B), in agreement with the study reported 
by others [107]. 
 
2.3.4 Macrophage responses enhanced by hyperglycemia exacerbates 
inflammatory conditions 
To ask if broadly increased macrophages in tissues would render multi-organ 
proinflammatory states, we tested hyperglycemic mice with other inflammatory 
challenges. Doxorubicin is a chemotherapy drug that could lead to renal injury 
(doxorubicin nephropathy) through glomerulosclerosis and tubulointerstitial nephritis 
[93]. Previous studies have shown that doxorubicin nephropathy is tightly associated with 
macrophage-mediated inflammation resulting in histological and functional injury [93, 
108, 109]. In our experiments, mice with and without hyperglycemia were given 
doxorubicin at a nephropathy-effective dose (30 mg/kg) and a sub-effective dose (20 
mg/kg) [92]. As shown in Figure 2.5 A, non-diabetic control mice developed proteinuria, 
an indicator of kidney injury, only when doxorubicin was given at 30 mg/kg, while remain 
asymptomic at 20 mg/kg. However, mice with hyperglycemia displayed hypersensitivity 
to doxorubicin, and showed proteinuria even when the doxorubicin dose was 20 mg/kg. 
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In addition, at 30 mg/kg, though both control and hyperglycemic mice developed 
proteinuria, the latter group was more severe. Subsequent tissue histological studies 
confirmed macrophage infiltration associated with doxorubicin-induced injury. As shown 
in Figure 2.5 B-C, kidneys from doxorubicin (30 mg/kg)-treated, control mice displayed 
scattered, small interstitial inflammatory foci with F4/80+ macrophages, whereas 
kidneys from the same-treated hyperglycemic mice displayed large, diffused areas of 
inflammation with increased macrophage accumulation. Indeed, predisposition of 
F4/80+ macrophages in diabetic kidneys was seen prior to doxorubicin treatment, and 
doxorubicin brought about additional macrophage infiltration. As expected, diabetic mice 
treated with insulin displayed doxorubicin-induced injury as that which had occurred in 
the control, non-diabetic mice (Figure 2.5 A-C). 
 
We also tested another inflammatory condition, DSS-induced colitis, and again observed 
that hyperglycemic mice displayed further exacerbated consequences. As shown in Figure 
2.6 A-B, upon induction of colitis with 2% DSS, mice with hyperglycemia developed much 
more severe cases of colitis, indicated by faster body weight decline and worse clinical 
symptoms (e.g. diarrhea) than control, non-diabetic mice. Subsequently, the colitic 
hyperglycemic mice succumbed to the condition in 8-9 days, whereas control non-
diabetic mice generally lasted to 12-15 days. Dissection of intestines on day 6 during DSS 
treatment revealed much more severe intestinal loss in hyperglycemic mice than that in 
non-diabetic mice (Figure 2.6 C). Colon sections confirmed that hyperglycemic mice 
compared to non-diabetic controls suffered more deteriorated tissue damage (Figure 2.6 
D) associated with higher levels of MPO (Figure 2.6 E), suggestive of increased PMN 
infiltration into the intestines. Analyses of macrophages in colon tissues (Figure 2.6 F) 
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found increased numbers in mucosa and submucosa in hyperglycemic mice even prior to 
colitis induction. Macrophages were also found in smooth muscle layers underlying 
mucosa where macrophages were normally scarce under healthy conditions. Together, 
these results further support our findings suggesting that animals under hyperglycemia 
are much more prone to exaggerated inflammatory response, and that broadly increased 
macrophages in tissues play a critical role. 
 
2.3.5 Inflammatory response in ob/ob mice 
In addition to mice with STZ-induced type 1 diabetes, we have also studied inflammatory 
response in ob/ob mice, which had displayed obesity and mild/moderate levels of 
hyperglycemia due to insulin resistance [110].  As shown in Figure 2.7 A, the fasting level 
of blood glucose in 10-12-week-old ob/ob mice was around 200 mg/dl compared to 164 
± 22 mg/dl in healthy wild type mice. We observed slight, or insignificant, increases in 
macrophages in peritonea of ob/ob mice compared to WT mice (Figure 2.7 B). Zymosan-
induced peritonitis tested in ob/ob mice failed to detect significant, but only slight, 
increases of PMN infiltration (Figure 2.7 C) and IL-6 expression (Figure 2.7 D). No 
significant increases in F4/80+ macrophages were observed in the liver or kidneys in 
ob/ob mice (Figure 2.7 E). Treating ob/ob mice with 2% DSS failed to induce severe colitis 
(Figure 2.7 F-G). In fact, ob/ob mice displayed resistance to the colitic condition, as also 
reported by others [111, 112]. Therefore, ob/ob mice, though with moderate 
hyperglycemia, do not display an enhanced systemic inflammatory state similarly to mice 
under STZ-induced type 1 diabetes, suggesting that broadly increased macrophages in 
various tissues, but not hyperglycemia per se, play a key role in enhancing PMN 
infiltration and tissue injuries during inflammation under diabetes.    
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2.4 Disscussion 
Chronic disease conditions, although many are restricted in specific local tissues, often 
lead to systemic changes in the host immunological system. As demonstrated previously, 
we found that animals with ongoing colitis, diabetes, lung inflammation and other chronic 
conditions display an alteration of host inflammatory response and significantly 
enhanced PMN function, which not only exacerbates the existing condition, and also leads 
to overstated reaction when facing a new inflammatory challenge [1-3]. The mechanisms 
governing the PMN inflammatory response under different conditions are varied and are 
incompletely understood. 
 
In this study, we further investigated the mechanisms that enhance PMN response under 
diabetes-associated hyperglycemia versus those under active colitis. As shown by our 
results, while PMN response is enhanced under both conditions, the mechanisms 
involved are different. Under colitis, IL-17 plays a principle role; IL-17 elevated at the 
post-acute/chronic stage of colitis promotes granulopoiesis and primes PMN response 
and function [1, 2]. IL-17 also primes tissue macrophages, leading to increased 
capabilities of inflammatory cytokine production which in turn promotes PMN 
infiltration. Neutralization of IL-17 reverses the enhanced PMN infiltration in colitic mice. 
However, the role of IL-17 in STZ-induced diabetes is negligible; neutralization of IL-17 
does not reverse the enhanced PMN response, nor does it alleviate the proinflammatory 
state. Instead, chronic hyperglycemia leads to increases in macrophages in a wide range 
of tissues, resulting in tissue hypersensitivity toward inflammatory challenge. As shown 
in the study, substantially increased macrophage numbers in the peritoneum of diabetic 
mice led to elevated levels of proinflammatory cytokines, which potently promoted PMN 
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recruitment during zymosan-induced peritonitis. Significantly increased numbers of 
macrophages were also observed in the liver, kidneys, and intestines. Upon inflammatory 
challenges, the increased macrophages in these organs predispose tissues to exaggerated 
inflammatory reaction, elevating risks of tissue injury. Testing three inflammatory 
conditions including acute peritonitis, doxorubicin-induced nephropathy and DSS-
induced colitis obtained consistent result; all supporting the conclusion that excess 
macrophages in tissues create a proinflammatory state, which synergizing with PMN 
priming, exaggerate inflammatory reactions. Insulin treatment reverses hyperglycemia 
and also the proinflammatory state in diabetic mice.   
 
Where and how are the increases in macrophage infiltration of tissues originating under 
the diabetic condition? Our studies have revealed at least two mechanisms. One is 
through the increase in monocyte production. We show that, instead of bone marrow, the 
spleen is the primary site where increased monocytes are produced in diabetic mice. The 
spleen serves as an important organ for monocyte production as per reports in recent 
years [101-103]. We also show that the increased monocytes under diabetes are 
Ly6C+CD11b+; hence they are tissue-infiltrating and contribute to increased tissue 
macrophages. The mechanism through which diabetes induces the spleen to boost 
monocyte production remains unclear, though increased MCP-1 produced from diabetic 
endothelial cells may play a role [35]. MCP-1 also promotes monocyte infiltration into 
peripheral tissues to replenish macrophages. The second mechanism responsible for 
elevation of tissue macrophages is through macrophage proliferation in situ. In diabetic 
mice, significantly increased macrophage proliferation was observed in peritonea, liver, 
kidney, and intestines. However, we failed to detect these proliferative macrophages 
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skewing toward the M2 phenotype; a polarization that is suggested to associate with 
macrophage proliferation [104, 113, 114]. In addition, we also failed to detect 
macrophages skewing toward the M1 phenotype in hyperglycemic tissues. Nevertheless, 
the substantially increased reservoir of macrophages in tissues augments tissue 
sensitivity toward inflammation, rendering vulnerability to inflammation-associated 
injury. Moreover, we found that ob/ob mice, though being associated with moderate 
levels of hyperglycemia, do not display increased macrophage infiltration in tissues, and 
thus do not exhibit a significantly enhanced systemic inflammatory state.  As leptin-
deficient mice, ob/ob mice have been suggested to be associated with defectiveness of 
certain macrophage/monocyte functions, due to the critical role of leptin in the activation 
of macrophages and monocytes [112, 115, 116]. However, this could also suggest that 
insulin resistance per se does not cause the systemic inflammation and that our 
observations under STZ-induced type I diabetes/hyperglycemia may not apply to the 
insulin resistance condition and/or the early stage of type 2 diabetes prior to b-cell 
dysfunction.  
 
In conclusion, the study demonstrates that diabetes is different from chronic colitis and 
induces a systemic proinflammatory state primarily through broadly increasing the 
macrophage population in various organ tissues. Though additional investigation is 
needed to further define the mechanisms, strategies aiming to reduce monocytosis in the 
spleen and limit macrophage proliferation in tissues may become important for 
controlling diabetic complications in conjunction with hyperglycemia mitigation. 
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Figure 2.1 Distinctions of enhanced PMN response in mice with STZ-induced diabetes 
and DSS-induced colitis  
A) STZ-induced diabetes/hyperglycemia. Mice were s.c. injected with STZ (25mg/kg, 5x 
or 50 mg/kg, 5x) or the vehicle (Ctl). Blood glucose levels were measured to confirm the 
establishment of hyperglycemia. Once blood glucose level (GLU) reached 200 mg/dl, one 
group of STZ mice were treated with insulin twice a day to convert hyperglycemia. B) 
Enhanced PMN infiltration in diabetic mice (1 month after STZ injection) during 
zymosan-induced peritonitis. PMN infiltration into peritoneum was tested at 0, 2, 4, 6, 8, 
16 h post-zymosan injection. C) Enhanced PMN infiltration in both colitis and diabetes. 
Healthy control, colitis (12 days of DSS, with or without anti-IL-17 treatments) and STZ 
mice with different GLU (1 month after STZ injection, with or without insulin or anti-IL-
17 treatments) were tested for PMN infiltration at 2 h post zymosan-induced peritonitis. 
D) DSS-induced colitis and IL-17 level in serum. 2% DSS in drinking water was 
continuously applied, and body weight loss was monitored for the establishment of colitis. 
Serum IL-17 levels were evaluated by ELISA. E) Serum cytokine levels in two disease 
models. Cytokine levels in serum were evaluated by ELISA. F) PMN ROS production upon 
PMA challenge. Bone marrow PMN (1x106) from healthy, colitis and STZ mice were 
loaded with 1 mM luminol followed by the stimulation with PMA (1µM), and 
chemiluminescence was detected at 37°C in relative light units (RLU) every 30 seconds 
over 30 minutes. G) Peak values of PMN ROS curves upon PMA challenge. n=8-10 
mice/group. * P<0.05, ** P<0.01, *** P<0.001 versus respective controls. (Since STZ 
diabetic mice with different GLU (200-350 mg/dl vs >350 mg/dl) established the similar 
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phenotype according to our study, the following results and figures will not further 
distinguish these two groups.) 
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Figure 2.2 Intensified peritonitis under diabetes is associated with locally increased 
proinflammatory macrophages.  
A) Increased proinflammatory cytokine level under diabetes (STZ) and colitis during 
zymosan-induced peritonitis.  IL-6 and CXCL1 levels in peritoneum and serum were 
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detected by ELISA at 2 h post-zymosan challenge. B) Increased number of F4/80+ 
peritoneal macrophages (Mφ) from mice with hyperglycemia compared to healthy mice 
or colitic mice without induction of peritonitis. C) In vitro zymosan challenge of 
peritoneal macrophages. Peritoneal macrophages obtained by peritoneal lavage were 
challenged in vitro with zymosan (0.1mg/ml). IL-6, CXCL1, IL-1β and TNF-α secreted 
into the culture media at a series of time points were assayed by ELISA. D-E) Adoptive 
transfusion of PMN from healthy (CMTMR labeled, red color) and STZ (or STZ with 
insulin treatment; CSFE labeled, green color) mice (1:1 ratio mixed, 3x106 PMN/recipient) 
into healthy, STZ or STZ with insulin recipients, followed by testing PMN infiltration 
during peritonitis. Figure shows the microscopic analysis of infiltrated PMN from all 
types of donors in peritoneal lavage after inducing peritonitis for 2 h, and the total 
numbers of all types of donor PMN infiltrated at 2 h post zymosan challenge. n=6-8 
mice/group. * P<0.05, ** P<0.01, *** P<0.001 versus respective controls. 
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Figure 2.3 Hyperglycemia induces broad macrophage infiltration in multiple organ 
tissues.  
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A, B) Macrophages were labeled with F4/80 by IHC or IF staining in livers and kidneys 
from healthy, STZ (1-month and 5-month of hyperglycemia), and STZ mice with insulin 
treatment (1-month). C, D) F4/80+ macrophages in IF staining were quantified as the 
corrected total cryosection fluorescence (CTCF) using ImageJ. E) Undetermined 
phenotype of F4/80+ macrophages in liver and kidney from STZ 1-month mice. F4/80+ 
(green) macrophages were co-stained with the M1 and M2 markers (red), CD86 and 
Dectin-1, respectively. Control M1 and M2 macrophages were induced from mouse bone 
marrow derived monocytes in vitro by overnight treatment with LPS (100ng/ml) + IFNγ 
(20ng/ml) and IL-4 (20ng/ml), respectively. F) Fluorescence quantification of liver and 
kidney sections from Fig 3E, as CTCF using ImageJ. All results represent at least three 
independent experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls. 
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Figure 2.4 Monocytosis and local macrophage proliferation in diabetic mice.  
A, B) Populations of PMN (black) and monocytes (red) in the peripheral blood, spleen 
and bone marrow analyzed by flow cytometry. Cells in the peripheral blood were labeled 
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with antibodies against Gr-1 and F4/80. Splenocytes and bone marrow cells were labeled 
with antibodies against Ly6C and Ly6G. C, D) Local macrophage proliferation in livers 
and kidneys from STZ mice. Tissues were co-stained with antibodies against F4/80 (red) 
as a macrophage marker and Ki-67 (green) as a cell proliferating marker. IF staining were 
quantified as CTCF using ImageJ. All results represent at least three independent 
experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls. 
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Figure 2.5 Augmented macrophage inflammatory response under hyperglycemia 
intensifies doxorubicin nephropathy.  
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A) Doxorubicin-induced nephropathy/proteinuria. Healthy and STZ (1 month, with or 
without insulin treatment) mice were i.v. injected with one dose of doxorubicin (20 mg/kg 
or 30 mg/kg). Urine samples were collected daily and urine albumin/proteinuria was 
tested by ELISA. n = 6 mice/group. B) F4/80 IF staining of same kidney samples from 
Figure 2.5 C were quantified as the corrected total cryosection fluorescence (CTCF) using 
ImageJ. C) Macrophages infiltrated in to kidneys were labeled with F4/80 by IHC 
staining. Kidney samples were obtained from control, STZ or STZ with insulin mice at day 
7 of doxorubicin (30 mg/kg, one dose) administration. Results represent at least three 
independent experiments with n=6. ** P<0.01, *** P<0.001 versus respective controls. 
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Figure 2.6 Exaggerated DSS-induced colitis in hyperglycemic mice.  
A) Body weight loss and survival curve of diabetic mice during DSS-colitis. 2% DSS in 
drinking water was continuously applied to control, STZ or STZ with insulin treatment 
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mice. B) Disease activity index (DAI) was evaluated on day 6 of DSS administration. C, D) 
Colon lengths and H&E staining of colon tissues at day 6. E) MPO assays of colon 
specimen with the same length (2 mm each, 3 specimens from 1 colon) that were 
randomly dissected from the entire colon followed by the homogenization. F) Enhanced 
infiltration of macrophages in the colon tissue of STZ mice. Macrophages were labeled 
with F4/80 by IF staining and quantified as CTCF using ImageJ. n=6 mice/group. 
*P<0.05, ** P<0.01, ***P<0.001 versus respective controls. 
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Figure 2.7 Comparison of systemic inflammation in C57BL/6 WT mice, type 1 diabetic 
WT mice induced by low dose STZ (1-month) and ob/ob mice (10-12 weeks old).  
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A) Fasting blood glucose levels. B) Peritoneal macrophage numbers. Note that no 
significant difference between WT healthy and ob/ob mice. C, D) Mildly increased PMN 
and elevated serum IL-6 in ob/ob mice at 2h of zymosan-induced peritonitis. E) 
Macrophages in livers and kidneys from WT healthy mice, WT diabetic mice and ob/ob 
mice, labeled by F4/80 via immunofluorescence staining. Fluorescent images were 
quantified using ImageJ. F, G) ob/ob mice exhibited only mild colitis with 2% DSS 
treatment. n=6 mice/group. *P<0.05, ** P<0.01, ***P<0.001 versus respective controls.  
 
 
 
 
  
55 
3     IDENTIFICATION OF LPS-PRIMED CD11B+ LEUKOCYTES AS THE 
EFFECTIVE CARRIER OF SHIGA TOXIN 2 CAUSING HEMOLYTIC 
UREMIC SYNDROME IN MICE 
 
3.1 Introduction 
Shiga toxin (Stx)-producing E. coli (STEC) are vicious food-borne pathogens that cause 
over 2 million acute illnesses annually worldwide, among which several thousand require 
hospitalization and hundreds succumb to death [41, 46, 117, 118]. Severe bacteria-induced 
enteritis with heavy diarrhea, both watery and bloody, is the major manifestation of STEC 
infection; however, the fatality sometimes occurs when the subsequent, life threatening 
complication hemolytic uremic syndrome (HUS) develops [5, 7, 38, 39]. The HUS 
condition, characterized by hemolytic anemia, acute kidney failure (uremia) and 
thrombocytopenia, often happened abruptly at the post-acute, or even the recovery stage 
of STEC-induced enteritis. Different from STEC infection that is restricted in intestines, 
HUS development is associated with the spread of Stx to target organs such as kidneys, 
where high affinity cell surface receptors such as globotriaosylceramide (Gb3) mediate 
Stx internalization, resulting in cellular toxicity [9, 48, 119, 120].  Two types of toxins, Stx1 
and Stx2, can be produced by STEC, with Stx2 possessing much higher potency of toxicity. 
No specific therapeutics are available for treatment of HUS, and that traditional 
antibiotics against bacteria show promotion of toxin expression from the lysogenized 
phage that typically carries the Shiga toxin (Stx) gene, thus tend to exacerbate the disease 
condition [43]. Another challenge for clinicians is the inability to predict which STEC-
infected patients would develop severe HUS and which would simply recover from the 
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early enteritis as indicators for clinical tests predicting HUS occurrence are still lacking 
[42].  
 
One major dilemma in HUS is the mystery of how Stx travels from STEC-infected 
intestines to kidneys. The possibility of passive dissemination, though not been 
completely excluded, has been considered low as no free Stx have been detected in the 
serum of HUS patients [121, 122]. Instead, circulating leukocytes have been suggested to 
serve as the carrier that delivers Stx to distant organs [10, 11]. In humans, some studies 
implicate neutrophils are the carrier. These studies reported observations of Stx direct 
binding to human neutrophils [10, 50] and the interference of the binding by LPS, 
suggesting that Toll-like receptor 4 (TLR4) is likely the receptor [51, 52]. However, other 
studies either failed to replicate Stx binding to human neutrophils or demonstrated that 
the binding was unspecific or weak, raising uncertainty of whether neutrophils to be the 
true carrier [53, 54]. Stx binding to leukocytes has also been shown in an in vitro study 
co-incubating Stx with isolated, total porcine peripheral leukocytes; however, this study 
did not reveal which population of leukocytes bound to the toxin and whether these 
leukocytes deliver toxin in vivo leading to HUS [55]. In mice, a study demonstrated that 
Stx2 is capable of binding to murine neutrophils, but the binding is through Gb3, leading 
to toxin internalization [56]. This study not only contradicts to the finding in humans in 
which Stx binding to neutrophils is independent of Gb3 [9, 52], but also raises the 
question of whether neutrophils would deliver the toxin in the body without degrading it 
intracellularly. In addition to these dilemmas, a recent study reported the finding of Stx 
in serum microvesicles [123], further baffling the exact carrier for Stx elusive. One 
particular drawback, as it worthy to mention, is that most experiments previously for 
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identifying the toxin carrier were in vitro cell binding assays, relevant minimally to the 
actual disease development; approaches are thus needed to directly determine the Stx 
carry in vivo that leads to HUS. 
 
In this study, we employ the LPS-Stx2 murine HUS model [74, 124] and further examine 
peripheral blood for the role in Stx carry and delivery and HUS-causing in vivo. Our data 
show that circulating myeloid leukocytes of CD11b+ in LPS-primed mice are highly 
effective in carrying of Stx2 in vivo. Brief exposure of these leukocytes to Stx2, even ex 
vivo, results in toxin binding and enables their capability to cause HUS in vivo.  In 
addition, we demonstrate for the first time that LPS-induced systemic inflammation 
significantly alters myeloid leukocytes to become highly capable Stx2 carriers, which in 
conjunction with enhanced leukocyte infiltration in toxin-afflicted tissues, aggravate 
kidney damage and accelerate the HUS condition. 
 
3.2 Materials & Methods 
3.2.1 Murine LPS-Stx2 HUS model 
LPS priming Stx2-induced HUS (LPS-Stx2 HUS) in mice [74] was established for the 
study. C57BL/6 mice (6-10 weeks old, 18-22 g) purchased from the Jackson Laboratory 
were housed in a pathogen-free animal facility. Stx2 purified from STEC was obtained 
from the Phoenix Laboratory at Tufts Medical Center (Boston, MA). To induce HUS in 
mice, one dose LPS (300 g/kg, Sigma-Aldrich) was first administered intraperitoneally 
(i.p.) to prime the mice. After 24 h, Stx2 was given via i.p. at the dose of 500 ng/kg. The 
injections of Stx2 were performed on the same mice for three times at every 24 h interval. 
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The appropriate dose of Stx2 to induce HUS was determined in initial pilot studies, in 
which various doses ranging from 100 ng/kg to 100 g/kg were tested (data not shown). 
Body weight loss was monitored after LPS and Stx2 administrations; peripheral blood 
samples were collected at due point for analyses. 
 
3.2.2 Peripheral blood work 
Peripheral blood was collected by cardiac puncture with anti-coagulation (0.1 ml of 3.8% 
sodium citrate per ml of blood). After centrifugation (150 x g, 10 mins, 4 °C), blood was 
separated into platelet-rich plasma (PRP), white blood cells (WBC) and red blood cells 
(RBC). PRP was collected followed by further centrifugation (5000 x g, 10 mins, 4 °C) to 
obtain platelets (PLT) and platelet-free plasma (PFP). WBC were isolated from the buffy 
coat followed by lysis of RBC using RBC lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 
mM EDTA). In some experiments, WBC were further separated into CD11b+ and CD11b- 
leukocyte sub-populations using a PE-conjugated anti-mouse CD11b antibody 
(BioLegend) and EasySep™ release mouse PE positive selection kit (STEMCELL 
Technologies). To determine peripheral reticulocytes, 3 drops of isolated RBC were mixed 
with 1 drop of Reticulocyte Stain (Sigma-Aldrich; 10 mins, room temperature) followed 
by smearing on a microscope slide and counting of reticulocytes per 1000 RBC. Increasing 
of reticulocytes in blood is an indicator of hemolytic anemia under HUS. Blood urea 
nitrogen (BUN) levels were determined by spectrophotometer using a BUN reagent set 
(Pointe Scientific). Plasma creatinine levels were determined using Creatinine 
Colorimetric Assay Kit (Cayman Chemical). Elevated BUN and creatinine indicate renal 
dysfunction during HUS development. 
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3.2.3 Adoptive transfer 
To transfer blood components from LPS-Stx2 induced HUS mice to non-HUS recipients, 
peripheral blood samples were collected from donor HUS mice 4 h after the 2nd Stx2 
administration, followed by separation into WBC, RBC, PLT and PFP. Adoptive transfer 
was then performed by transfusion intravenously (i.v.) of donor PFP (0.3 ml) or cell 
samples including WBC (1 x 106), RBC (1 x 108) and PLT (5 x 108) in 0.3 ml PBS via a tail 
vein into recipient mice that had been primed with one dose LPS (300 g/kg) 24 h earlier. 
Blood component transfer from HUS mice to recipients was repeated every 24 h for two-
three rounds. Control experiments were performed by transferring blood components 
from healthy donor mice or the carrier solution PBS to LPS-primed mice. Prior to and 
after the adoptive transfer, the recipient mice were monitored for body weight change. 
The recipient mice were euthanized after the 3rd adoptive transfer and blood urea 
nitrogen (BUN) and creatinine, as well as peripheral reticulocytes and thrombocytopenia, 
were determined.   
 
3.2.4 Ex vivo Stx2 treatment 
Peripheral WBC, RBC or cells from each fraction of bone marrow (1 x 106 cells 
each), or PLT (5 x 108) from LPS-primed mice or healthy mice were incubated with Stx2 
(10 ng/ml) ex vivo in PBS (0.5 ml, 30 min, 25°C). The cells were then washed thoroughly 
with PBS (5 x) to remove excess Stx2 followed by suspension in PBS (150 µl) and adoptive 
transfer into LPS-primed recipients (1 x 106 total WBC, 1 x 106 CD11b+ or CD11b- 
leukocytes, 1 x 108 RBC, 5 x 108 PLT, or 1 x 106 bone marrow cells per mouse). Control 
experiments were done by adoptive transfer of mice with cells that had not incubated with 
Stx2 or with the carrier solution PBS.   
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3.2.5 Bone marrow (BM) cell isolation and fractionation 
Mouse BM were harvested from femur and tibia bones. After lysis of RBC, whole BM cells 
were fractionated using discontinuous Percoll™ (GE Healthcare) density gradients 
consisting of layers of 75%, 60%, 50%, and 40% of Percoll density solutions (2 ml per 
layer) prepared following the sequential decreasing order from the bottom to the top in 
15 ml centrifugation tubes. Prepared BM cells in 2 ml PBS were laid on top of the gradients 
followed by centrifugation at 1800 x g for 40 min (18°C). Four cell-rich bands were formed 
at the density interfaces of 0-40%, 40-50%, 50-60% and 60-75% (fractions I, II, III and 
IV, respectively) after the centrifugation and cells in each band were collected. After wash 
with PBS to remove excess Percoll, cells in different fractions were determined by flow 
cytometry for granulocytes (Ly6G+), monocytes (Ly6Chigh), myeloid leukocytes 
(CD11b+Gr-1+), B lymphocytes (B220+), etc.  Antibodies with fluorophore conjugations 
for flow cytometry were obtained from (BioLegend). 
 
3.2.6 Stx2-FITC and toxin-cell binding determination 
Fluorescein isothiocyanate (FITC) (Pierce) was chemically conjugated to Stx2 using the 
EZ-Label FITC Protein Labeling Kit (Thermo Scientific). Briefly, Stx2 (0.1 mg) was 
incubated with FITC (10 µg) in borate buffer (0.1 ml, pH 8.5) for 2 h (25°C). The labeling 
reaction was then quenched with 100 mM Tris buffer (pH 7.5), followed by extensive 
dialysis against PBS to remove the excess uncoupled FITC. For cell surface labeling, WBC 
(1 x 106) isolated from LPS-primed mice and non-primed mice were incubated with Stx2-
FITC (10 ng/ml) in 0.5 ml PBS for 30 min. A special note is that the concentration of Stx2-
FITC used in the labeling should reference the in vivo effective dosage of Stx2, which is 
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very low; over-use of Stx2-FITC produces high degree non-specific binding. After 
labeling, the cells were washed, followed by labeling with Pacific Blue™-conjugated anti-
mouse CD11b (BioLegend) and flow cytometry. 
 
3.2.7 Statistical analyses  
Data represent at least three independent experiments and are expressed as the mean ± 
SEM. The reported p value was 2-tailed. Differences were considered statistically 
significant at P < 0.05, as analyzed using the Student t-test for paired samples and one-
way ANOVA for k > 2 samples. 
 
3.3 Results 
3.3.1 Establishment of Murine HUS model using LPS-Stx2 
To induce HUS, C57BL/6 mice were first given one dose of LPS (300 µg/kg, i.p.). After 24 
h, the same mice were intraperitoneally administrated with Stx2 (500 ng/kg), followed 
by two additional Stx2 administrations, each given in a 24 h interval (the scheme is shown 
in Figure 3.1 A). As shown in Figure 3.1 B-H, LPS priming followed by Stx2 
administrations (LPS-Stx2) rapidly induced HUS development, demonstrated by body 
weight loss, thrombocytopenia, anemia (increased peripheral reticulocytes), and 
significantly elevated creatinine and BUN levels in the circulation indicative of renal 
dysfunction. Kidney failure was evident after 2 days following the LPS-Stx2 treatments 
when urinary output became deficit. All mice treated with LPS-Stx2 succumbed to HUS 
in 3-4 days. Comparably, mice primed with LPS alone experienced transient, slight weight 
loss, without signs of thrombocytopenia, anemia or renal dysfunction. Mice given Stx2 
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without LPS priming developed similar, but delayed appearance or mild HUS symptoms; 
these mice would also progress to HUS lethality but require higher doses of toxin (1-3 
µg/kg), more frequent treatments (> 4 treats), and/or a longer time period. These results 
were in agreement with previous studies by others using Stx2-induced HUS mouse 
models with LPS priming [74, 125]. 
 
3.3.2 WBC in the peripheral blood served as the potential carriers of Stx2 
As Stx2 was given intraperitoneally, it needed to travel to kidneys in order to cause kidney 
damage. To determine if circulating blood played a role in carrying Stx2 to kidneys, 
peripheral blood samples were collected from mice with LPS-Stx2 induced HUS, in which 
when the HUS condition was developing (4 h after the 2nd Stx2 administration). These 
HUS blood samples were separated into platelet-free plasma (PFP), platelets (PLT), RBC 
and WBC by differential centrifugations, followed by adoptive transfer (i. v.) of each 
component into recipient mice that were similarly primed by LPS but without Stx2 
administration (Figure 3.2 A). A total of three rounds of blood component transfer was 
performed in every 24 h interval. As shown in Figure 3.2 B-C, recipient mice, though never 
been directly exposed to Stx2, developed HUS after receiving WBC from LPS-Stx2 donors; 
the mice transferred with WBC demonstrated characteristic HUS symptoms including 
body weight loss, thrombocytopenia and renal dysfunction. Indeed, these WBC causing 
HUS in recipient mice were in the way similar to that when LPS-Stx2 was used to induce 
HUS. In contrast, recipient mice in which PFP, PLT, or RBC were transferred from the 
same LPS-Stx2 donors failed to develop HUS. In conclusion, these results showed that 
WBC from HUS-inflicted mice were capable of transferring the disease to non-HUS 
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animals, suggesting that WBC serve as the Stx2 carrier, bearing Stx2 to distant target 
organs. Other blood components such as PFP, PLT and RBC were not the toxin carrier.  
 
To further confirm that WBC can carry Stx2, hence contribute to HUS development and 
kidney failure, we isolated WBC from non-HUS mice and tested if ex vivo exposure of 
WBC to Stx2 would enable the capability of causing HUS. In these experiments, WBC, as 
well as other types of cells, isolated from peripheral blood of LPS-primed mice were 
incubated with Stx2 (20 ng/ml) ex vivo for 30 min (25°C) followed by thorough washing, 
prior to transfer into recipient mice. Since bone marrow (BM) contained reservoirs of 
WBC, these cells were also isolated, similarly treated with Stx2 ex vivo, and transferred 
into recipients. As shown in Figure 3.3, ex vivo Stx2-treated WBC and BM cells rapidly 
induced HUS in recipient mice, inferring that WBC bound to Stx2 during the ex vivo 
exposure, carried toxin in vivo and caused disease. Conversely, ex vivo exposure to Stx2 
did not enable RBC or platelets to cause HUS.  
 
3.3.3 Identification of CD11b+ leukocytes as the carriers of Stx2 
Since WBC are heterogeneous, comprising CD11b+ myeloid leukocytes and CD11b- 
lymphocytes (Figure 3.4 A), we performed further separation by antibody-mediated 
positive selections using immunomagnetic beads. Subsequent exposure of CD11b+ and 
CD11b- cells to Stx2 ex vivo and then testing the capability of causing HUS in vivo 
demonstrated that only CD11b+ myeloid leukocytes carried Stx2 leading to HUS. As 
shown in Figure 3.4, between the two populations of peripheral WBC, both being treated 
with Stx2 ex vivo, CD11b+ leukocytes but not CD11b- lymphocytes effectively induced HUS 
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in recipient mice. We also further separated BM cells by Percoll density gradients, which 
enriched CD11b+ myeloid leukocytes to high density fractions between the Percoll 
densities of 50-60% and 60-70% (fractions III and IV) (Figure 3.5 A). In agreement with 
our other studies, the CD11b+ fraction III contained Ly6Chigh monocytes and immature 
Ly6G+ granulocytes (approximately 40% and 60%, respectively), while the highest 
density, CD11b+ fraction IV were nearly completely mature Ly6G+ granulocytes (> 95%) 
(Figure 3.5 B). There were low density fractions (I and II), which contained chiefly CD11b- 
lymphocytes, progenitors and stroma cells. After cell separation and washing, different 
fractions of BM leukocytes were exposed to Stx2 ex vivo by co-incubation, prior to transfer 
into recipient mice. As shown in Figure 3.5 C, the fraction IV granulocytes displayed a 
strong capability to carry Stx2 and cause HUS in recipients, while the fraction III 
displayed partial effects and induced relatively mild, delayed HUS symptoms. Conversely, 
BM cells from the low density fractions (I and II) failed to induce HUS in vivo. In 
conclusion, these results together support that CD11b+ leukocytes in the WBC population 
serve as the Stx2 carrier during HUS development. 
 
3.3.4 Pre-administration of LPS modulated the binding and delivery of 
Stx2 by CD11b+ leukocytes in vivo 
Interestingly, we found that CD11b+ leukocytes isolated from LPS-primed mice and mice 
without priming displayed different potencies in inducing HUS, even the same ex vivo 
Stx2 exposure ensued. As shown in Figure 3.6 A-C, after co-incubation with Stx2, CD11b+ 
leukocytes from LPS-primed mice exhibited much stronger capability of inducing HUS 
than those from healthy mice (non-LPS priming); after the adoptive transfer, recipient 
mice with the former leukocytes demonstrated faster body weight loss and more profound 
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renal dysfunction than mice with the latter. Since the number of CD11b+ leukocytes used 
for adoptive transfer was the same for either donor mice, the varied effectiveness in 
inducing HUS suggests that LPS priming significantly augmented CD11b+ leukocytes 
binding to and/or carrying of Stx2, whereas leukocytes without priming had only weak 
toxin delivery capacity. Binding of CD11b+ leukocytes with FITC-labeled Stx2 confirmed 
this fact, showing increased frequencies of toxin binding to leukocytes from LPS-primed 
mice than those from non-primed mice (Figure 3.6 D). LPS priming of mice might also 
enhance leukocyte infiltration into Stx2-inflicted organs, further aggravating tissue 
damage.  Together, our results suggest that LPS-induced systemic inflammation plays a 
significant role in promoting HUS; it “primes” CD11b+ leukocytes for more binding to 
Stx2, rendering these leukocytes to become effective toxin disseminator that leads to 
HUS.  
 
3.4 Discussion 
Due to the broad sources of STEC transmission such as consumption of contaminated 
food and water, or direct contact with infected persons or animals, outbreaks of STEC 
occur frequently each year causing millions of illnesses. While STEC infection is restricted 
to the intestines, patients, especially children and elders, are at risk for developing the 
Stx-caused, severe extra-intestinal complication HUS. Approximately 10% of STEC-
infected patients develop HUS in clinics, and acute kidney failure is among the most 
common reasons leading to lethality. STEC produce two types of bipartite toxins, Stx1 and 
Stx2, both of which contain an A subunit and five B subunits (AB5). The B subunits 
mediate cell attachment through binding to cell surface receptors, while the A subunit 
possesses enzymatic activity that cleaves the adenine nucleotide in ribosomal RNAs and 
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DNA, resulting in ribosome and gene damage [7, 8, 126, 127]. A few cell types including 
renal epithelial cells express the high affinity receptors for the B subunits, rendering 
kidneys to be the vulnerable toxin targets [48, 128, 129]. However, STEC are non-invasive 
bacteria restricted in intestines; for causing cell damage in kidneys, STEC-produced Stx 
must be transported from intestines to the kidney. No specific diagnostic methods 
predicting HUS, in part, for the fact that mechanisms lead to Stx spread from bacteria-
infected intestines to kidneys remain unclear. The establishment of murine models of Stx-
induced HUS is an important step in research, allowing for further mechanistic 
investigations and identification of the Stx delivery pathway in vivo. Interestingly, the 
initial studies of these models indicated that, in addition to Stx administration, LPS 
administration is preferable to induce a lethal condition of HUS that mimics pathological 
processes in human disease [74, 125]. Merely administration of Stx2 induces less severe 
and partial symptoms of HUS, or requires higher doses and/or a longer period for the 
disease development [74]. 
 
Utilizing the LPS-primed mice to induce HUS by Stx2 (LPS-Stx2 HUS model [74, 124, 
125]) in mice, we asked whether, or which circulating blood cells have the ability to carry 
toxin to kidneys leading to HUS in vivo. Four sequential experiments were performed in 
this study and together led to the conclusion that CD11b+ myeloid leukocytes act as the 
exclusive toxin carrier, which directly binds to Stx2 and carries the toxin to kidneys 
causing lethal HUS in vivo. First, we harvested peripheral blood cells and the cell-free 
plasma from LPS-Stx2 treated mice in which severe HUS was developing, and transferred 
these components to recipient mice that had no prior Stx exposure. These experiments 
showed that peripheral WBC, but not other cells, from mice with HUS carried toxin and 
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transferred the disease to recipients. These experiments also concluded that Stx spreads 
through cell carriers as the cell-free plasma from the same HUS mice failed to transfer 
disease, suggesting this component being devoid of toxin. Also for the same reason, it is 
concluded that circulation of extracellular microvesicles [123] is not the main channel for 
the toxin dissemination.  Second, we tested circulating blood cells from non-HUS mice 
briefly exposed to Stx2 ex vivo for the ability of causing HUS in vivo after adoptive 
transfer into recipients. The results showed that WBC, as well as WBC-rich BM cells, after 
ex vivo exposure to Stx2 gained capability of inducing HUS, suggesting that these cells 
directly bound to Stx2 ex vivo and carried the toxin in vivo. In the third experiments, we 
further separated peripheral WBC into CD11b+ myeloid leukocytes and CD11b- others, and 
defined that the former leukocytes serve as the Stx2 carrier. Brief exposure to Stx2 ex vivo 
is sufficient for CD11b+ myeloid leukocytes to cause HUS in vivo. In all the “trans”-
induced HUS experiments performed by adoptive transfer of Stx2-exposed leukocytes, 
renal dysfunction was evident, suggesting the Stx2-bore leukocytes carrying toxin to 
kidneys via circulation. Lastly, we tested leukocytes from mice with and without LPS 
priming for capturing of Stx2 ex vivo followed by causing HUS in vivo. These experiments 
demonstrate that LPS priming significantly increases CD11b+ leukocytes for binding to 
toxin.  
 
LPS promoting Stx2-induced HUS in mice has been shown in the initial disease 
modeling [74, 124, 125] , but the mechanisms accountable for this effect were unclear. 
From this study, we predict that the mechanisms are two-fold, both attributing to LPS-
induced systemic inflammatory response. One is that the elicited inflammatory response 
promotes leukocyte infiltration and leukocyte-mediated damaging function. In Stx-
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induced HUS, enhanced leukocyte infiltration and damaging in kidneys certainly 
aggravates injury deposited by Stx toxicity, hence accelerating kidney failure. Another 
critical mechanism for LPS promoting Stx-induced HUS, as revealed by this study, is that 
LPS treatment alters CD11b+ leukocytes, resulting in the production of highly effective 
Stx2 carriers. It is unclear how LPS achieves this, whether through directly signaling on 
leukocytes, or by inducing inflammatory cytokines, which then “re-program” leukocytes, 
leading to changes of the cell surface molecular expression and the presentation of Stx2 
receptor(s). From our data, it appears that both the leukocyte receptor number and the 
binding capability are increased in LPS-primed mice compared to those in non-primed 
littermates (Figure 3.6 D). These views of LPS aggravating Stx2-induced HUS in mouse 
models match with clinical cases of STEC-associated HUS in humans, in which STEC 
infection imparts enteritis along with the Stx toxin. Perhaps, the systemic inflammation 
subsequent of the initial enteritis leads to innate leukocyte changes, rendering some 
CD11b+ leukocytes to become potent Stx carriers. Indeed, this conception is in agreement 
with other studies of intestinal inflammation [1, 118, 130], in which innate leukocytes were 
observed changing protein expressions, and also would provide an explanation of why 
severe HUS in clinics often occurs at the post-acute or even resolution stage, a delayed 
phase until leukocytes becoming effective toxin carrier. Clearly, these postulations of LPS 
promotes Stx-induced HUS requires further investigations, and important findings of 
Stx2 receptors on leukocytes and how dysregulated inflammation promotes HUS will 
bring medical innovations, both diagnosis and therapeutics, for treating STEC-associated 
HUS.  
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Figure 3.1 LPS-Stx2 induced HUS in mice. 
A) The induction schemes. Mice were primed with LPS (300 µg/kg, i. p.) a day prior to 
three consecutive Stx administrations (500 ng/kg, i. p. every 24 h). Controls were mice 
administrated with LPS alone or PBS (saline). B-F) Determination of HUS. Starting from 
the LPS treatment, mouse body weight (B) was recorded daily. C) Mouse survival rate 
through the HUS induction. The clinical diagnostic triad including hemolytic anemia, 
E 
F 
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thrombocytopenia and renal dysfunction detected by assaying increases in peripheral 
reticulocytes (D), reduction of peripheral platelets (E), and increases in the plasma 
creatinine and urea nitrogen (BUN) levels (F). Data represent over three independent 
experiments; n= 10, * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls. 
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Figure 3.2 HUS transmission by peripheral white blood cells (WBC) of Stx2-induced HUS 
mice. 
Peripheral blood was obtained from LPS-Stx2 -treated mice (donors) during HUS 
development. The blood components including WBC, RBC, platelets (PLT) and PLT-free 
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plasma (PFP) were separated and transferred intravenously (i. v., every 24 h) into mice 
(recipients) that were administrated with LPS (300 µg/kg, i. p.) a day earlier (priming). 
A) The experimental scheme; B-D) HUS development in recipient mice. Data show the 
body weight loss (B), and the appearance of thrombocytopenia (C) and renal dysfunction 
indicated by evaluated plasma creatinine and urea nitrogen (BUN) levels (D) 72 h after 
the adoptive transfer. Data represent four independent experiments; n = 6; * p < 0.05, ** 
p < 0.01, *** p < 0.001 versus controls in which recipient mice were administrated (i. v.) 
with saline. 
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Figure 3.3 Ex vivo exposure to Stx2 confers WBC capability causing HUS. 
Peripheral blood WBC, RBC and PLT, as well as bone marrow (BM) cells, were isolated 
from LPS-primed, non-HUS mice. The cells were then incubated ex vivo with Stx2 (10 
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ng/ml in PBS) for 30 min (25°C), followed by thorough wash and transfer (i. v.) into other 
LPS-primed mice (recipients). A) The experimental scheme; B) HUS development in 
recipient mice assessed by body weight loss (B), thrombocytopenia (C) and renal 
dysfunction (D). Data represent four individual experiments; n = 6; * p < 0.05, ** p < 
0.01, *** p < 0.001 versus controls in which recipient mice were administrated (i. v.) with 
saline. 
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Figure 3.4 CD11b+ myeloid leukocytes carry Stx2 and cause HUS in vivo. 
Peripheral WBC from LPS-primed, non-HUS mice were further separated into CD11b+ 
and CD11b- leukocyte populations by antibody-facilitated positive selection. After brief 
80 
incubation (30 min) with Stx2 (10 ng/ml in PBS) ex vivo and wash, two populations of 
leukocytes were transferred (i. v.) into different, LPS-primed recipient mice (A). HUS 
development in recipient mice assessed by body weight loss (B), thrombocytopenia (C) 
and renal dysfunction (D). Data represent two individual experiments; n = 6; * p < 0.05, 
** p < 0.01, *** p < 0.001 versus controls in which recipient mice were administrated       
(i. v.) with saline.  
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Figure 3.5 Myeloid leukocytes from BM also have the capability of carrying Stx2. 
Total BM cells from LPS-primed, non-HUS mice were fractionated by Percoll density 
gradients into non-myeloid cells (Fr. I and II) and myeloid leukocytes (Fr. III and Fr. IV) 
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following a protocol described previously. The separated populations were incubated with 
incubated with Stx2 (10 ng/ml in PBS) ex vivo, followed by thorough wash and transfer 
into other LPS-primed mice (recipients) (A).  HUS development in recipient mice 
assessed by body weight loss (B), thrombocytopenia (C) and renal dysfunction (D). Data 
represent two individual experiments; n = 6; * p < 0.05, ** p < 0.01, *** p < 0.001 versus 
controls in which recipient mice were administrated (i. v.) with saline. 
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Figure 3.6 LPS priming promotes CD11b+ leukocytes binding to Stx2. 
CD11b+ leukocytes isolated from LPS-primed and non-primed donors were incubated 
with Stx2 (10 ng/ml in PBS) ex vivo, followed by washing and transfer into recipient mice 
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with LPS priming. A) Experimental scheme. B) Increased frequencies of Stx2-FITC 
binding to CD11b+ leukocytes from LPS-primed mice than those from non-primed mice 
analyzed by flow cytometry. C-E) HUS development in recipient mice assessed by body 
weight loss (C), thrombocytopenia (D) and renal dysfunction (E). Data represent two 
individual experiments; n = 6; * p < 0.05, ** p < 0.01, *** p < 0.001 versus controls in 
which recipient mice were administrated (i. v.) with saline. 
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4 CONCLUSIONS 
Sub-acute/chronic inflammation dynamically regulates innate immune cell response. In 
the first study using DSS-induced colitic mice and STZ-induced diabetic mice as sub-
acute/chronic inflammatory models, we demonstrate that different from colitis, diabetes 
presents a systemic proinflammatory state primarily through broadly increasing the 
macrophage population in various organ tissues. Once facing a secondary inflammatory 
challenge, increased macrophages not only directly provide enhanced local 
proinflammatory responses, but also recruit increased number of PMN to the 
inflammatory site, which both result in exacerbated tissue damage. Reversing 
hyperglycemia using insulin significantly relieves such exacerbation, which emphasizes 
the clinical importance of maintaining a stable and normal blood glucose level in diabetic 
patients. Though additional investigation is needed to further define the mechanisms of 
how macrophages are modified under hyperglycemic condition, strategies aiming to 
reduce monocytosis in the spleen and limit macrophage proliferation in tissues may 
become important for controlling diabetic complications in conjunction with 
hyperglycemia mitigation. 
 
In the study of identifying the carrier of Stx2 that causes HUS, we demonstrate that 
CD11b+ leukocytes in the peripheral blood bind to and deliver Stx2 to the target end 
organs in vivo. More importantly, we discover that pre-existing inflammation induced by 
low dose LPS escalates the capability of CD11b+ leukocytes delivering Stx2 and inducing 
HUS. This may provide an explanation of the “window period” observed in HUS patients, 
where the potential carriers of Stx may undergo “re-programming” due to the pre-existing 
inflammation (enteritis), to become a higher affinity toxin carrier, resulting in a sudden 
88 
and robust HUS. Clearly, the mechanism of such “re-programming” on toxin carrying 
ability of CD11b+ leukocytes require further investigations. Nevertheless, important 
findings addressing the mechanisms of how CD11b+ leukocytes (or its sub-type) become 
better Stx carriers will contribute to early detection and therapeutic innovations in 
treating STEC infection-associated HUS.  
 
Several studies by others suggest that PMN in human is capable of binding Stx [10, 11, 50, 
129], possibly through TLR4 as the binding site [52]; however, very few in vivo evidence 
supports the role of PMN as the sole carrier of Stx that is responsible for directly causing 
HUS. Those studies also failed to address why adults other than children and seniors have 
a very low incidence of HUS, given that PMN composes more than 50% of the WBC 
population circulating in a normal adult. Interestingly, our further studies using murine 
HUS model suggest that a subtype of CD11b+ WBC, rather than PMN, which are CCR3+ 
eosinophils, exhibits the highest capability of binding to Stx2 upon LPS-priming (data not 
shown). Although it requires more intensive investigation on whether this group of cells 
carries and delivers Stx2 to target organs causing HUS, our observation may provide an 
important alternative route to better understand the pathogenesis of such a devastating 
disease HUS, and the relationship between Stx, the carrier cells, and the target distal 
organs such as the kidneys. 
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